Case Study: Elsie Biotechnologies achieves faster oligo screening and 80% lower NGS analysis costs with LatchBio

Elsie Biotechnologies builds a scientist-centric RNA discovery platform on Latch to empower the wet lab ($50m acquisition by GSK)

Elsie Biotechnologies, a San Diego biotech company developing oligonucleotide therapeutics, faced a significant challenge in getting bioinformatics tools into the hands of their scientists. This bottleneck meant the feedback loop for gaining insights from their data could take up to a month, severely hindering their research and development speed for new RNA-based treatments.

To solve this, Elsie Biotechnologies implemented the LatchBio platform. This solution enabled their scientists to design, analyze, and run bioinformatics pipelines themselves without needing to code. The results were transformative: the team achieved an 80% reduction in NGS analysis costs, accelerated their oligo screening, and improved experimental design. This efficiency ultimately contributed to their success, culminating in a $50 million asset acquisition by GSK.

Elsie Biotechnologies

Dillon Flood

Co-Founder